Cryoablation+Ipilimumab+Nivolumab in Melanoma

This study is testing a combination approach for melanoma (skin cancer) that has stopped responding to immunotherapy. It combines cryoablation (freezing tumors to destroy them) with a dual immunotherapy regimen using ipilimumab and nivolumab. The idea is that destroying a tumor with cold may release signals that help the immune system attack remaining cancer cells. **You may be eligible if:** - You are over 18 and have unresectable (inoperable) melanoma - Your cancer has progressed after treatment with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab, ipilimumab) - Your doctor plans to start you on dual immunotherapy with ipilimumab and nivolumab - You are healthy enough to tolerate dual immunotherapy **You may NOT be eligible if:** - You are not medically eligible for dual immunotherapy - You have conditions that would make cryoablation unsafe Talk to your doctor to see if this trial is right for you.